研究

Takenaka K, Ito T, Komatsu N, Yamaguchi H, Kirito K, Tomita A, Togano T, Tanaka T, Sugimoto Y, Murai K, Wada H, Kurokawa T, Koike M, Gotoh A, Maekawa T, Kubuki Y, Akagi T, Yamauchi T, Edahiro Y, Ikeda K, Kondo T, Tanaka H, Miyazaki Y, Saito TI, Shimoda K, Kada A, Saito AM, Kiyoi H, Akashi K, Matsumura I, Takaori A.

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.

Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Patah P, Takahashi A, Månsson BD, Favaro E, Fukuhara N.

Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3.

Makita S, Izutsu K, Mishima Y, Kumode T, Kuroda J, Kanemura N, Fukuhara N, Shimada K, Mori C, Kawasaki A, Miyake T, Maruyama D.

Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.

Nakamura F, Ishiyama K, Suzuki R, Maruyama H, Onishi Y, Usuki K, Koh H, Takenaka K, Saiki R, Ogawa S, Matsumoto K, Takahashi T, Hosomichi K, Zaimoku Y, Yoshimura K, Matsumura I, Akashi K, Nakao S.

Phase II study of the triple combination of rabbit ATG, ciclosporin and eltrombopag in patients with transfusion-dependent aplastic anaemia: West Japan Hematology Study Group (W-JHS) AA02 trial.

Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jiménez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F.

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial

Morschhauser F, Salles G, Sehn LH, Herrera AF, Friedberg JW, Trněný M, Lenz G, Sharman JP, Herbaux C, Burke JM, Matasar M, Collins GP, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Pinto A, Rai S, Izutsu K, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Jiang Y, McCall B, Chohan S, Sugidono M, Yan M, Lee Batlevi C, Tilly H, Flowers CR.

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma

Izutsu K, Watanabe M, Toubai T, Tsukamoto T, Maruyama D, Kumode T, Fukuhara N, Ogawa N, Satomi N, Nishimura Y, Honda H, Chyla B, Takizawa J.

Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study

Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Sakaida E, Maeda Y, Yamauchi T, Kiyoi H.

Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data

Suzuki T, Jo T, Yoshifuji K, Kondo T, Doki N, Kanda Y, Nishida T, Onishi Y, Asada N, Fukuda T, Sawa M, Hasegawa Y, Serizawa K, Ota S, Tanaka M, Yoshimitsu M, Atsuta Y, Kanda J.

Impact of methotrexate-dosing regimens for GVHD prophylaxis on clinical outcomes of HLA-matched allogeneic HSCT.

Ishiyama K, Yamazaki M, Maruyama H, Hosono N, Yamaguchi H, Asada N, Tanimoto K, Sugiura H, Usuki K, Yoshimura K, Ogawa S, Kanakura Y, Matsumura I, Akashi K, Nakao S.

Efficacy of ciclosporin monotherapy in non-severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study